FEG
GILD icon

Financial Enhancement Group’s Gilead Sciences GILD Stock Holding History

Financial Enhancement Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30
Closed -$2K – 297
2020
Q3 		$2K Buy
+30
New +$2.08K ﹤0.01% 214
2019
Q2 		– Sell
-504
Closed -$33K – 300
2019
Q1 		$33K Buy
+504
New +$33.5K 0.01% 150

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Financial Enhancement Group's GILD Position: Q4 2020 in Review

Financial Enhancement Group sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 30 shares — an estimated $2K sold.

Financial Enhancement Group first reported a position in GILD in Q1 2019 and held it in 2 quarters. The position peaked at $33K in Q1 2019. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

  • Financial Enhancement Group reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
  • Financial Enhancement Group sold 30 Gilead Sciences shares in Q4 2020, an estimated $2K.
  • Financial Enhancement Group first reported a position in Gilead Sciences in Q1 2019 and held it in 2 quarters.
  • Financial Enhancement Group's Gilead Sciences position peaked at $33K in Q1 2019.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Financial Enhancement Group's 13F filing for Q4 2020, filed 10 Feb 2021.